7月18日港股公司回购一览 | 代码 | 简称 | 回购股数 | 回购金额（万 | 回购最高价 | 回购最低价 | 年内累计回购金额 | | --- | --- | --- | --- | --- | --- | --- | | | | （万股） | 港元） | （港元） | （港元） | （万港元） | | 00345 | VITASOY INT'L | 104.40 | 966.71 | 9.260 | 9.250 | 13723.43 | | 02039 | 中集集团 | 126.28 | 868.93 | 7.020 | 6.700 | 5600.66 | | 00670 | 中国东方航 空股份 | 175.00 | 503.98 | 2.940 | 2.850 | 57578.93 | | 02319 | 蒙牛乳业 | 20.00 | 339.30 | 16.980 | 16.940 | 22787.27 | | 00732 | 信利国际 | 200.00 | 240.00 | 1.210 | 1.190 | 9587.27 | | 09896 | 名创优品 | 5.70 | 199.43 | 35 ...

| 股票名称 | 回购数 | 回购额 | 年累计回购数量 | 年累计回购数量/总 | | --- | --- | --- | --- | --- | | | | | (股) | 股本 | | VITASOY INT'L(00345) | 104.40 万 | 966.71 万 | 1457.40 万 | 1.358% | | 中集集团(02039) | 126.28 万 | 868.93 万 | 861.08 万 | 0.280% | | 百胜中国(09987) | 1.65 万 | 625.18 万 | 283.99 万 | 0.760% | | 中国东方航空股份 (00670) | 175.00 万 | 503.98 万 | 9620.80 万 | 1.859% | | 贝壳-W(02423) | 63.49 万 | 400.00 万 | 1081.36 万 | 0.300% | | 蒙牛乳业(02319) | 20.00 万 | 339.30 万 | 475.00 万 | 0.121% | | 百胜中国(09987) | 6.80 万 | 320.00 万 | 283.99 万 | 0.760% | | ...

Core Viewpoint - As of July 18, 160 stocks reached their 52-week highs, with notable performances from China New Economy Investment (00080), Aoyuan Group Equity (02905), and Zhong An Holdings Group (08462) showing high growth rates of 288.89%, 55.28%, and 50.00% respectively [1][2]. Summary by Category 52-Week High Performers - China New Economy Investment (00080) closed at 0.440, with a peak price of 0.700, achieving a growth rate of 288.89% [2]. - Aoyuan Group Equity (02905) closed at 0.218, with a peak price of 0.250, achieving a growth rate of 55.28% [2]. - Zhong An Holdings Group (08462) closed at 0.221, with a peak price of 0.228, achieving a growth rate of 50.00% [2]. - Other notable performers include Hualian International (00969) with a growth rate of 40.13% and Zhongke Bio (01237) with a growth rate of 37.25% [2]. Additional High Performers - Wanma Holdings (06928) closed at 0.550 with a growth rate of 30.43% [2]. - Lepu Biopharma-B (02157) closed at 7.940 with a growth rate of 24.54% [2]. - Other stocks with significant growth include ZhiJianYueDong (06860) at 17.14% and China Jindian Group (08281) at 17.12% [2]. 52-Week Low Performers - The document also lists stocks that reached their 52-week lows, with XI Ernan CO-U (09311) showing a decline of 16.10% [6]. - Other notable declines include XI Ernan CO (07311) at -12.62% and Haotian International Construction Investment (01341) at -5.70% [6].

证券时报·数据宝统计显示，7月16日有22家香港上市公司进行了股份回购，合计回购1520.22万股，回购 金额3266.20万港元。 中国东方航空股份回购数量250.00万股，回购金额726.31万港元，回购最高价为2.950港元，最低价为 2.890港元，年内累计回购金额5.64亿港元；中集集团回购数量94.74万股，回购金额642.45万港元，回购 最高价为6.850港元，最低价为6.580港元，年内累计回购金额4281.44万港元；中国旭阳集团回购数量 138.00万股，回购金额348.59万港元，回购最高价为2.540港元，最低价为2.500港元，年内累计回购金额 1.58亿港元。 以金额进行统计，7月16日回购金额最多的是中国东方航空股份，回购金额为726.31万港元；其次是中 集集团，回购金额为642.45万港元；回购金额居前的还有中国旭阳集团、蒙牛乳业等。回购数量上看， 7月16日回购股数最多的是中电光谷，当日回购量为400.80万股；其次是中国东方航空股份、捷利交易 宝等，回购数量分别为250.00万股、200.00万股。 值得关注的是，本次回购726.31万港元的中国东方航空股份，年内则进行 ...

Group 1 - The article reports on share buybacks conducted by various companies on July 16, 2025, with China Eastern Airlines having the largest buyback amount of 7.2631 million yuan for 2.5 million shares [1][2] - A total of 20 companies participated in the buyback, including notable names such as Mengniu Dairy, IGG, and Modern Dental [1] - The cumulative buyback amounts and percentages of total shares for each company are detailed, indicating varying levels of commitment to share repurchase programs [2] Group 2 - China Eastern Airlines (00670) repurchased 2.5 million shares, totaling 7.2631 million yuan, representing 1.782% of its total share capital [2] - Other companies like CIMC (02039) and China Xuyang Group (01907) also engaged in buybacks, with CIMC repurchasing 947,400 shares for 6.4245 million yuan, accounting for 0.220% of its total shares [2] - The buyback activities reflect a strategic move by these companies to enhance shareholder value and signal confidence in their financial health [1][2]

Group 1 - The article reports on stock buybacks conducted by various companies on July 15, 2025, with a total of 20 companies participating in the buyback program [1] - The company with the largest buyback amount was Wan Ka Yi Lian (01762), repurchasing 7.14 million shares for a total of 5.06 million yuan [1][2] - Other notable buybacks include Mengniu Dairy (02319) with 300,000 shares for 4.97 million yuan and China International Marine Containers (02039) with 613,100 shares for 4.03 million yuan [2] Group 2 - The cumulative buyback figures for the year show Wan Ka Yi Lian (01762) has repurchased a total of 17.37 million shares, representing 0.981% of its total share capital [2] - Other companies with significant cumulative buyback percentages include Kangchen Pharmaceutical (01681) at 5.926% and China Aluminum Can (06898) at 3.900% [2] - The buyback activity reflects a strategic move by these companies to enhance shareholder value and signal confidence in their financial health [1][2]

据香港联交所最新股权披露信息显示，近日，康臣药业(01681)获大股东、董事局主席安猛先生持续增持。智通财经APP了解到，安猛先生于今年7月10日和7 月11日连续增持康臣药业，合计增持27.80万股，买入均价为11.34港元，彰显大股东对康臣药业未来发展的信心。 | 或后了或 | | 大型米/电量/角色 ( 以人用心理 ( ) ( ) ( ) ( ) ( ) ) ( ) ) ( ) ) ( ) ) ( ) ) ( ) ) ( ) ) ( ) ) ( ) ) ( ) ) ( ) ) ( ) ) ( ) ) ( ) ) ( ) ) ( ) ) ( ) ( ) ) ( | 三人/香蕉 - 大家 - 一 | | CE | | 日本日本日 2017年 10:00 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | der H | | | 東京人 新田市 中国 | (H/H/ | | | DA20250712E00019 | | 1104 (L) | 251,000(L | HKD 11.3600 | 230,660,455(L) | 27.06(L)11 ...

7月4日，"格隆汇·中期策略峰会·2025"于深圳盛大开幕。其中，在"格隆汇·金格奖"ESG卓越公司评选中，康臣药业（01681.HK）荣获"ESG社会责任卓越企 业"奖项。 "ESG社会责任卓越企业"奖项旨在表彰在社会公益、员工权益保障、社区共建等方面展现卓越担当的企业，重点关注其在乡村振兴、普惠包容性发展等国家 战略中的实践成果，树立商业向善的行业榜样。 同日，康臣药业管理层亮相峰会路演环节。秉承着"承古拓新，良药济民"的企业使命，康臣药业在医药行业中已拥有较高的品牌知名度及患者的认可度，努 力"打造肾科旗舰，成为多专科领先的一流医药企业"。 稳增长与高分红并举，持续回馈股东价值 从财报数据来看，2013年上市至今，康臣药业的业绩一直处于"稳健增长"姿态。 截止2024年，康臣药业的营收年复合增长率达16.1%，净利润年复合增长率达17.6%，其中近三年ROE均保持在20%以上，远高于同期同业表现情况。 在业绩稳健增长的背景之下，康臣药业也持续通过高比例分红派息积极回馈广大股东。 根据WIND数据统计显示，过往十年（2014-2024年），康臣药业年平均派息比率超30%。其中，2024年公司派息比率更是进 ...

Summary of Key Points Core Viewpoint - On July 7, 34 Hong Kong-listed companies conducted share buybacks, totaling 30.99 million shares and an aggregate amount of HKD 921 million [1][2]. Group 1: Buyback Details - Tencent Holdings repurchased 1.002 million shares for HKD 501 million, with a highest price of HKD 502.000 and a lowest price of HKD 494.400, bringing its total buyback amount for the year to HKD 38.542 billion [1][2]. - AIA Group repurchased 5.5 million shares for HKD 377 million, with a highest price of HKD 69.150 and a lowest price of HKD 68.050, totaling HKD 16.352 billion in buybacks for the year [1][2]. - Founder Holdings repurchased 10.386 million shares for HKD 1.174 million, with a highest price of HKD 1.150 and a lowest price of HKD 1.110, accumulating HKD 3.541 million in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on July 7 was from Tencent Holdings at HKD 501 million, followed by AIA Group at HKD 377 million [1][2]. - In terms of share quantity, Founder Holdings had the most significant buyback with 10.386 million shares, followed by AIA Group with 5.5 million shares and China Electric Power Technology with 2.26 million shares [1][2].

Industry Overview - The pharmaceutical industry showed resilience in 2024, achieving steady growth despite challenges such as weak global economic recovery and inflationary pressures [18]. - The accelerated aging of the domestic population and rising chronic disease incidence provided long-term growth momentum for the pharmaceutical industry [18]. - The pharmaceutical industry is expected to enter a high-quality development phase as industry concentration increases and innovation capacity is enhanced [23]. Company Leadership and Management - The company appointed Mr. An Meng as Chief Executive Officer on January 17, 2024, following the resignation of Ms. Li Qian [4]. - The company’s Chairman, Mr. An Meng, was appointed as Chief Executive Officer on January 17, 2024, indicating a leadership transition [172]. - Professor Zhu Quan, aged 85, continues to serve as an executive director and chief scientist, focusing on product research and development since joining in August 2006 [181]. - The management team includes experts with extensive backgrounds in both academia and the pharmaceutical industry, enhancing the company's strategic direction [185]. Financial Performance - In 2024, the Group recorded sales revenue of approximately RMB2.97 billion, representing an increase of approximately 14.6% over last year [24]. - Profit attributable to equity shareholders of the Company was approximately RMB0.91 billion, representing an increase of approximately 16.1% over last year [24]. - The Group's annual profit attributable to equity shareholders was RMB 910,458,000, representing an increase of approximately 16.1% compared to RMB 784,534,000 in 2023 [98]. - The average gross profit margin for 2024 was approximately 75.6%, an increase of 1.4 percentage points from 74.2% in 2023 [81]. - The Group's profit before taxation for 2024 was RMB 1,020,106,000, reflecting an 18.1% increase from RMB 863,703,000 in 2023 [77]. Sales and Revenue Growth - Sales revenue of the Consun Pharmaceutical Segment amounted to approximately RMB2.53 billion in 2024, representing a year-on-year increase of approximately 15.3% [28]. - Sales revenue of kidney medicines amounted to approximately RMB1.99 billion in 2024, representing a year-on-year increase of approximately 14.5% [28]. - The flagship product, Uremic Clearance Granules, achieved sales revenue of approximately RMB1.88 billion, representing a year-on-year increase of approximately 13.9% [28]. - Sales revenue of medical contrast medium was approximately RMB0.17 billion in 2024, representing a year-on-year increase of approximately 9.0% [33]. - The sales revenue of the Gynaecology and Paediatrics Department reached approximately RMB0.36 billion in 2024, representing a record high growth of approximately 23.3% year-on-year [35]. Research and Development - The State introduced policies to support R&D of new drugs and optimize the review process, promoting high-quality industry development [18]. - The Group entered into a patent and technology transfer agreement with China-Japan Friendship Hospital for "Astragalus Spike Granules" and established a project for new-drug research [44]. - The Group's R&D efforts led to the publication of 4 SCI papers, enhancing the academic evidence for kidney-related products [41]. - The Group's nephrology innovative drug SK-08 tablets entered phase I clinical trials ahead of schedule, while applications for SK-09 tablets and other drugs have been submitted [44]. - The Group established the "Consun – Dongda Innovation Research Center of Nephrology" to strengthen research and commercialization in kidney diseases [44]. Strategic Focus and Market Position - The company is focused on enhancing its core competitiveness through innovation and transformation in response to market pressures [18]. - The Group's strategic focus includes key areas such as nephropathy, imaging, gynecology, and pediatrics to consolidate market position [24]. - The Group's strategic focus for 2025 includes "Winning tough battles, deepening compliance, and enhancing services" to achieve high-quality development [66]. - The Group plans to increase investment in R&D and promote technological innovation to ensure market leadership in its products and services [67]. - The Group aims to leverage the growing health consumption trends to drive future growth in the pharmaceutical sector [18]. Compliance and Risk Management - The company aims to improve its compliance management system in 2025 to ensure adherence to laws and regulations across all business activities [68]. - Management continues to monitor key risk exposures, including operational, financial, and compliance risks, while adapting to national policy developments in the pharmaceutical industry [149]. - There were no significant non-compliance incidents with laws and regulations relevant to the Group's operations during the year ended December 31, 2024 [151]. Market Dynamics and Government Policies - Medical insurance cost control policies were deepened, expanding the scope of quantity procurement, which forced enterprises to innovate and improve competitiveness [18]. - The NHSA's efforts in 2024 include promoting fair and transparent inter-provincial drug pricing, which is expected to impact market dynamics [167]. - The Implementation Plan for Full-chain Support for the Development of Innovative Drugs was approved, emphasizing policy protection and optimizing evaluation mechanisms [156]. - The tenth batch of national centralized drug procurement was completed in December 2024, achieving a total of 500 drugs [163]. Operational Efficiency and Future Plans - The Group plans to enhance service quality and optimize customer experience through digital means in 2025 [72]. - The Group's operational policies include "Stabilizing Growth, Strengthening Compliance, and Training Internally" to ensure steady development [24]. - The construction of phase II of the production base in Xinjiang is progressing and is expected to be completed in Q1 2025, enhancing the production capacity of the Group's main products [56][58]. - In 2025, the Group aims to enhance operational efficiency and secure a favorable market position through precise market analysis and flexible strategic adjustments [66][67]. Employee and Financial Management - The total staff costs for the year ended December 31, 2024, were RMB 593,172,000, an increase from RMB 483,508,000 in 2023 [126]. - The Group hired a total of 3,164 employees as of December 31, 2024, compared to 3,127 employees in the previous year [126]. - The balance of inventories as of December 31, 2024, was RMB 289,677,000, a decrease of approximately 21.1% from RMB 367,087,000 as of December 31, 2023 [99]. - The Group's cash and bank balances as of December 31, 2024, were RMB 3,865,682,000, an increase of approximately 7.9% from RMB 3,583,204,000 as of December 31, 2023 [108].